Digest Réseau Comment ça marche
Réseau
/
Sociétés
Ga
Non vérifié

Gan & Lee Pharmaceuticals

Ce que nous écrivons

Fitness/Bien-êtreIndustrie pharmaceutiqueMédecine - DiversSantéSanté Publique

12 communiqués de presse

Voir tous les communiqués de presse
Press Release cover image
12/06/2026
Santé
Fitness/Bien-être
Médecine - Divers
Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S.
Source
Gan & Lee Pharmaceuticals
Émetteur
PR News Wire
1.00
0
Press Release cover image
09/04/2026
Santé
Fitness/Bien-être
Marché du travail
Lois/Droit
Fisc/Taxes
Médecine - Divers
Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide
Source
Gan & Lee Pharmaceuticals
Émetteur
PR News Wire
1.00
0
Press Release cover image
31/03/2026
Santé
Fitness/Bien-être
Médecine - Divers
Gan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2
Source
Gan & Lee Pharmaceuticals
Émetteur
PR News Wire
1.00
0
10/03/2025
Industrie pharmaceutique
Santé Publique
Économie
Start-up
Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or Obesity
Source
Gan & Lee Pharmaceuticals
Émetteur
PR News Wire
1.00
0
Press Release cover image
18/12/2024
Industrie pharmaceutique
Banque
Santé Publique
Science
Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)
Source
Gan & Lee Pharmaceuticals
Émetteur
PR News Wire
1.00
0
Press Release cover image
12/11/2024
Industrie pharmaceutique
Santé Publique
Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks
Source
Gan & Lee Pharmaceuticals
Émetteur
PR News Wire
1.00
0
Press Release cover image
11/11/2024
Industrie pharmaceutique
Santé Publique
ObesityWeek®️ 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults
Source
Gan & Lee Pharmaceuticals
Émetteur
PR News Wire
1.00
0
Press Release cover image
15/10/2024
Industrie pharmaceutique
Santé Publique
Gan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical Studies
Source
Gan & Lee Pharmaceuticals
Émetteur
PR News Wire
1.00
0
Press Release cover image
14/09/2024
Industrie pharmaceutique
Santé Publique
Biologie
Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)
Source
Gan & Lee Pharmaceuticals
Émetteur
PR News Wire
1.00
0
Press Release cover image
22/07/2024
Industrie pharmaceutique
Santé Publique
Biologie
Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial
Source
Gan & Lee Pharmaceuticals
Émetteur
PR News Wire
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0